Levipil XR 500 Tablet contains Levetiracetam 500 mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure activity. Levipil XR 500 is formulated as an extended-release tablet to provide a consistent plasma concentration, enhancing patient compliance by allowing once-daily dosing. It is generally well tolerated, with common adverse effects including somnolence, dizziness, headache, and fatigue. Dose adjustments may be necessary in patients with renal impairment. Levipil XR 500 should be used under medical supervision, with careful monitoring during therapy initiation and titration to minimize potential side effects and optimize therapeutic outcomes. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any tablet excipients. Caution is advised when used concomitantly with other central nervous system depressants. This medication should not be discontinued abruptly to avoid the risk of increased seizure frequency. Levipil XR 500 contributes significantly to seizure control, improving quality of life in patients with epilepsy.